The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Bookmark and Share

ASH 2020

3 - 8 Dec 2020
Online, Virtual, United States of America
Videos
News
Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive ...
Dr Ryotaro Nakamura - City of Hope, California, USA
Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive care in older patients with advanced MDS ( Dr Ryotaro Nakamura - City of Hope, California, USA )
17 Feb 2021
Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China
Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China
Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China ( Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China )
29 Jan 2021
The Burkitt lymphoma international prognostic index
Prof Adam Olszewski - Brown University, Providence, USA
The Burkitt lymphoma international prognostic index ( Prof Adam Olszewski - Brown University, Providence, USA )
24 Dec 2020
Results of venetoclax and azacitidine combination in chemotherapy ineligible unt...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with AML ( Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA )
22 Dec 2020
Long-term follow-up of low-intensity chemotherapy with combination therapy for r...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute lymphoblastic leukaemia patients ( Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA )
22 Dec 2020
Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumu...
Prof Evangelos Terpos - University of Athens, Athens, Greece
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and bortezomib ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL ...
Dr Liora Schultz - Stanford University School of Medicine, Palo Alto, USA
PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL after commercial tisagenlecleucel ( Dr Liora Schultz - Stanford University School of Medicine, Palo Alto, USA )
16 Dec 2020
Researchers trace the origin of blood cancer to early childhood, decades before ...
Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK
Researchers trace the origin of blood cancer to early childhood, decades before diagnosis ( Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK )
16 Dec 2020
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma
Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eri...
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma ( Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eric Smith )
15 Dec 2020
Survival analysis of newly diagnosed transplant-eligible multiple myeloma patien...
Dr Francesca Gay - University of Torino, Torino, Italy
Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomised Forte trial ( Dr Francesca Gay - University of Torino, Torino, Italy )
14 Dec 2020
ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosp...
Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy
ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine ( Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy )
11 Dec 2020
FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multi...
Dr Elena Zamagni - University of Bologna, Bologna, Italy
FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multiple myeloma patients ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )
10 Dec 2020
Clinical activity and safety of cevostamab in relapsed/refractory multiple myelo...
Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )
10 Dec 2020
ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia
Prof Andreas Hochhaus - Universitätsklinikum Jena, Jena, Germany
ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia ( Prof Andreas Hochhaus - Universitätsklinikum Jena, Jena, Germany )
10 Dec 2020
ASCENT: A phase II trial of induction, consolidation and maintenance in subjects...
Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA
ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk smouldering MM ( Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA )
9 Dec 2020
Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukae...
Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Nether...
Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of the ITCC-059 study ( Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands )
9 Dec 2020
MURANO: Sustained disease survival in CLL following venetoclax plus rituximab
Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands
MURANO: Sustained disease survival in CLL following venetoclax plus rituximab ( Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands )
9 Dec 2020
Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CL...
Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA
Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL ( Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA )
9 Dec 2020
Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
9 Dec 2020
ASH 2020: Targeted therapies in r/r multiple myeloma
Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar
ASH 2020: Targeted therapies in r/r multiple myeloma ( Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar )
8 Dec 2020
Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment
Prof Monica Bocchia - University of Siena, Siena, Italy
Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment ( Prof Monica Bocchia - University of Siena, Siena, Italy )
8 Dec 2020
Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve se...
Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA
Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve settings ( Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA )
8 Dec 2020
Treating acute leukaemias of ambiguous lineage
Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Ho...
Treating acute leukaemias of ambiguous lineage ( Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Hospital, USA )
8 Dec 2020
Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China...
Dr Shaji Kumar and Dr Wenming Chen
Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective ( Dr Shaji Kumar and Dr Wenming Chen )
8 Dec 2020
First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T31...
Dr Jorge Cortes - Augusta University, Augusta, USA
First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation ( Dr Jorge Cortes - Augusta University, Augusta, USA )
8 Dec 2020
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combina...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
8 Dec 2020
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin l...
Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data ( Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia )
8 Dec 2020
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil
Five year update of ECHELON-1 for classical Hodgkin lymphoma ( Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil )
8 Dec 2020
Off-the-shelf multi-virus specific T cells following haematopoietic stem cell tr...
Dr Bilal Omer - Baylor College of Medicine, Houston, USA
Off-the-shelf multi-virus specific T cells following haematopoietic stem cell transplantation ( Dr Bilal Omer - Baylor College of Medicine, Houston, USA )
8 Dec 2020
Blinatumomab and oral TKIs for the treatment of Ph ALL
Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA
Blinatumomab and oral TKIs for the treatment of Ph ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )
8 Dec 2020
D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL
Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA
D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )
8 Dec 2020
Real world management of multiple myeloma patients
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
Real world management of multiple myeloma patients ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )
8 Dec 2020
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-ye...
Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results ( Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany )
7 Dec 2020
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patien...
Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients ( Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain )
7 Dec 2020
FORTE trial: Impact of minimal residual disease on multiple myeloma patients
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy
FORTE trial: Impact of minimal residual disease on multiple myeloma patients ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )
7 Dec 2020
Evaluation of MRD negativity in patients with relapsed or refractory multiple my...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
7 Dec 2020
ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma
Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA
ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma ( Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma
Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma ( Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA )
7 Dec 2020
Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in ne...
Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA
Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML ( Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA )
7 Dec 2020
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelph...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Trea...
Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands
Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol ( Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands )
7 Dec 2020
Predictive factors for overall survival in chronic myeloid leukaemia patients: a...
Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy
Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study ( Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy )
6 Dec 2020
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potent...
Prof David Teachey - The University of Pennsylvania, Rutledge, USA
Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL ( Prof David Teachey - The University of Pennsylvania, Rutledge, USA )
6 Dec 2020
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukae...
Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia ( Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA )
5 Dec 2020

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation